Campbell De Morgan's ‘Observations on Cancer’,and their Relevance Today

De Morgan C. The Origin of Cancer. Considered with Reference to the Treatment of Disease. London: Churchill, 1872

De Morgan C. On cancer. Retrospect of Medicine 1874; 69: 34–9

De Morgan C. Observations on cancer. Lancet 1874; 1: 323–9

Pathological Society of London. Discussion on cancer. Lancet 1874; i: 334–6

Bruns P. Die Heilwirkung des Erysipels auf Geschwülste. Beitr Klin Chir 1887-1888; 3: 443

Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas (reprinted). Clin Orthop 1991; 262: 3–11

Coley W.B. Treatment of inoperable malignant tumour with the toxins of erysipelas and Bacillus prodigiosus. Trans Am Surg Assoc 1894; 12: 183–96

Nauts H.C. , McLaren J.R. Coley's toxins—the first century. Adv Exp Biol Med 1990; 267: 483–500

Takeuchi S. A new look at the history of tumour immunotherapy—for its fruitful future through overcoming the widespread cynicism. Hum Cell 1996; 9: 1–10 [in Japanese, with English abstract]

Rosenberg S.A. , Spiess P. , Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumour-infiltrating lymphocytes. Science 1986; 233: 1318–21

Dong C. , Flavell R.A. Th1 and Th2 cells. Curr Opin Hematol 2001; 8: 47–51

Clerici M. , Clerici E. , Shearer G.M. Tumor enhancement phenomenon: reinterpretation from a Th1/Th2 perspective. J Natl Cancer Inst 1996; 88: 461–2

Nishimura T. , Nakui M. , Sato M. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 2000; 46(Suppl): s52–61

Orditura M. , Romano C. , De Vita F. Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunol Immunother 2000; 49: 530–6

Stanford J.L. , Stanford C.A. , Grange J.M. Environmental echoes. Science Progr 2001; 84: 105–24

Rook G.A.W. , Zumla A. Advances in the immunopathogenesis of pulmonary tuberculosis. Curr Opin Pulm Med 2001; 7: 116–23

Grange J.M. , Stanford J.L. , Rook G.A.W. Tuberculosis and cancer: parallels in host responses and therapeutic approaches? Lancet 1995; 345: 1350–2

Grange J.M. , Stanford J.L. BCG vaccination and cancer. Tubercle 1990; 71: 61–4

Tan J.K. , Ho V.C. Pooled analysis of the efficacy of bacille Calmette-Guérin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993; 19: 985–90

Brandau S. , Böhle A. Therapy of bladder cancer with BCG: the mechanism behind a successful immunotherapy. Mod Asp Immunobiol 2001; 2: 37–41

Fine P.E. BCG: the challenge continues. Scand J Infect Dis 2001; 33: 243–5

Marchant A. , Goetghebuer T. , Ota M.O. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette–Guérin vaccination. J Immunol 1999; 163: 2249–55

Crispin R.G. , Rosenthal S.R. BCG vaccination and cancer mortality. Cancer Immunol Immunother 1976; 1: 139–42

Comstock G.W. , Martinez I. , Livesay V.T. Efficacy of BCG vaccination in the prevention of cancer. J Natl Cancer Inst 1975; 54: 835–9

Stanford J.L. , Stanford C.A. , Baban B. , Grange J.M. Therapeutic vaccination for cancer: the potential value of mycobacterial products. Int J Pharmaceut Med 1999; 12: 191–5

Association of the British Pharmaceutical Industry. Oncology Mission Report, US East Coast, November 2000. London: Association of the British Pharmaceutical Industry, 2001